 Raymond Estacio
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 19 | 2025 | 2004 | 1.750 |
Why?
| | Community Health Services | 3 | 2017 | 227 | 0.900 |
Why?
| | Diabetes Mellitus, Type 2 | 16 | 2025 | 2441 | 0.870 |
Why?
| | Albuminuria | 7 | 2023 | 183 | 0.860 |
Why?
| | Health Promotion | 4 | 2023 | 719 | 0.730 |
Why?
| | Case Management | 2 | 2012 | 64 | 0.670 |
Why?
| | Hypertension | 9 | 2016 | 1242 | 0.630 |
Why?
| | Community Health Workers | 2 | 2025 | 55 | 0.620 |
Why?
| | Antihypertensive Agents | 7 | 2016 | 485 | 0.570 |
Why?
| | Program Evaluation | 3 | 2017 | 875 | 0.530 |
Why?
| | Renin-Angiotensin System | 2 | 2024 | 82 | 0.520 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 4 | 2024 | 198 | 0.520 |
Why?
| | Primary Health Care | 4 | 2017 | 1680 | 0.510 |
Why?
| | Lipoproteins, LDL | 2 | 2017 | 127 | 0.500 |
Why?
| | Text Messaging | 2 | 2015 | 149 | 0.480 |
Why?
| | Risk Reduction Behavior | 2 | 2017 | 209 | 0.480 |
Why?
| | Glomerular Filtration Rate | 5 | 2024 | 711 | 0.440 |
Why?
| | Diabetes Mellitus | 3 | 2012 | 1001 | 0.440 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2024 | 566 | 0.430 |
Why?
| | Coronary Disease | 2 | 2012 | 385 | 0.390 |
Why?
| | Nursing Care | 1 | 2012 | 39 | 0.370 |
Why?
| | Colorado | 13 | 2025 | 4421 | 0.350 |
Why?
| | Patient Admission | 1 | 2012 | 182 | 0.340 |
Why?
| | Angiotensin Receptor Antagonists | 3 | 2024 | 89 | 0.330 |
Why?
| | Renin | 1 | 2009 | 32 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2024 | 1368 | 0.320 |
Why?
| | Phosphorus | 1 | 2009 | 93 | 0.300 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 759 | 0.300 |
Why?
| | Nursing Diagnosis | 1 | 2008 | 16 | 0.300 |
Why?
| | Blood Pressure | 7 | 2016 | 1736 | 0.290 |
Why?
| | Community-Institutional Relations | 1 | 2008 | 95 | 0.280 |
Why?
| | Cardiac Output, Low | 1 | 2008 | 66 | 0.280 |
Why?
| | Heart Rate | 2 | 2011 | 802 | 0.280 |
Why?
| | Middle Aged | 30 | 2025 | 31154 | 0.280 |
Why?
| | Drug Prescriptions | 1 | 2009 | 248 | 0.280 |
Why?
| | Tetrazoles | 1 | 2006 | 38 | 0.270 |
Why?
| | Aged | 21 | 2025 | 22103 | 0.270 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 36 | 0.260 |
Why?
| | Risk Factors | 11 | 2023 | 9765 | 0.260 |
Why?
| | Valine | 1 | 2006 | 81 | 0.260 |
Why?
| | Blood Pressure Determination | 2 | 2017 | 148 | 0.250 |
Why?
| | Diabetic Nephropathies | 3 | 2006 | 284 | 0.230 |
Why?
| | Lipids | 1 | 2008 | 625 | 0.230 |
Why?
| | Cohort Studies | 10 | 2012 | 5420 | 0.220 |
Why?
| | Humans | 43 | 2025 | 129650 | 0.210 |
Why?
| | Telemedicine | 1 | 2012 | 788 | 0.210 |
Why?
| | Nisoldipine | 4 | 2009 | 7 | 0.200 |
Why?
| | Enalapril | 4 | 2009 | 16 | 0.190 |
Why?
| | Follow-Up Studies | 9 | 2012 | 4897 | 0.190 |
Why?
| | Adult | 17 | 2022 | 35576 | 0.190 |
Why?
| | Diabetic Angiopathies | 5 | 2007 | 261 | 0.180 |
Why?
| | Medically Underserved Area | 2 | 2015 | 84 | 0.180 |
Why?
| | Proportional Hazards Models | 5 | 2012 | 1201 | 0.180 |
Why?
| | Renal Insufficiency | 1 | 2023 | 149 | 0.180 |
Why?
| | Disease Progression | 3 | 2024 | 2635 | 0.180 |
Why?
| | Male | 28 | 2025 | 63681 | 0.170 |
Why?
| | Life Style | 3 | 2012 | 460 | 0.170 |
Why?
| | Female | 28 | 2025 | 68776 | 0.160 |
Why?
| | Self Care | 2 | 2012 | 370 | 0.150 |
Why?
| | Health Literacy | 1 | 2021 | 161 | 0.150 |
Why?
| | Pilot Projects | 3 | 2025 | 1587 | 0.140 |
Why?
| | Poverty | 3 | 2017 | 496 | 0.140 |
Why?
| | Healthy Lifestyle | 1 | 2017 | 32 | 0.140 |
Why?
| | Prospective Studies | 7 | 2012 | 7133 | 0.140 |
Why?
| | Exercise | 1 | 2008 | 1925 | 0.130 |
Why?
| | Urban Population | 2 | 2017 | 441 | 0.130 |
Why?
| | Diabetic Neuropathies | 3 | 2006 | 96 | 0.120 |
Why?
| | Rural Population | 2 | 2025 | 518 | 0.120 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2008 | 126 | 0.120 |
Why?
| | Focus Groups | 2 | 2015 | 453 | 0.120 |
Why?
| | Educational Status | 1 | 2017 | 470 | 0.120 |
Why?
| | Triglycerides | 1 | 2017 | 527 | 0.120 |
Why?
| | Time Factors | 8 | 2024 | 6556 | 0.110 |
Why?
| | Accelerometry | 1 | 2015 | 93 | 0.110 |
Why?
| | Rural Health Services | 1 | 2015 | 111 | 0.110 |
Why?
| | Hyperlipidemias | 2 | 2005 | 126 | 0.110 |
Why?
| | Risk Assessment | 4 | 2011 | 3240 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 430 | 0.100 |
Why?
| | Diabetic Retinopathy | 2 | 2006 | 176 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7086 | 0.100 |
Why?
| | Bayes Theorem | 2 | 2024 | 375 | 0.090 |
Why?
| | Geographic Information Systems | 1 | 2011 | 42 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3628 | 0.090 |
Why?
| | Medically Uninsured | 1 | 2012 | 127 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2007 | 526 | 0.090 |
Why?
| | Registries | 2 | 2009 | 1896 | 0.090 |
Why?
| | Carotid Artery Diseases | 1 | 2011 | 64 | 0.090 |
Why?
| | Patient Compliance | 1 | 2015 | 565 | 0.090 |
Why?
| | Algorithms | 2 | 2008 | 1622 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2012 | 1501 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 676 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2024 | 10230 | 0.080 |
Why?
| | Myocardial Infarction | 3 | 2006 | 1022 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 1952 | 0.080 |
Why?
| | Kidney | 2 | 2024 | 1385 | 0.080 |
Why?
| | Fumarates | 1 | 2009 | 9 | 0.080 |
Why?
| | Health Maintenance Organizations | 1 | 2009 | 97 | 0.080 |
Why?
| | Urban Health Services | 1 | 2009 | 61 | 0.080 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 569 | 0.080 |
Why?
| | Comorbidity | 3 | 2009 | 1547 | 0.080 |
Why?
| | Risk Management | 1 | 2009 | 85 | 0.080 |
Why?
| | Amides | 1 | 2009 | 91 | 0.080 |
Why?
| | Logistic Models | 3 | 2009 | 1988 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2024 | 14518 | 0.070 |
Why?
| | Medical Errors | 1 | 2009 | 104 | 0.070 |
Why?
| | Diabetes Complications | 2 | 2009 | 224 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2009 | 1214 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 589 | 0.070 |
Why?
| | Minority Groups | 1 | 2010 | 249 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2009 | 1502 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2008 | 93 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 902 | 0.070 |
Why?
| | Young Adult | 2 | 2015 | 12426 | 0.070 |
Why?
| | Blood Glucose | 1 | 2017 | 2097 | 0.070 |
Why?
| | Motivation | 1 | 2012 | 546 | 0.070 |
Why?
| | Electrocardiography | 2 | 2008 | 608 | 0.070 |
Why?
| | Valsartan | 1 | 2006 | 27 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2012 | 2717 | 0.070 |
Why?
| | Health Status | 1 | 2011 | 755 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2006 | 152 | 0.060 |
Why?
| | Stroke | 3 | 2003 | 1071 | 0.060 |
Why?
| | Program Development | 1 | 2008 | 357 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 384 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1149 | 0.060 |
Why?
| | Creatinine | 2 | 2023 | 491 | 0.060 |
Why?
| | Quality Assurance, Health Care | 1 | 2007 | 318 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1274 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2006 | 273 | 0.060 |
Why?
| | Reagent Strips | 1 | 2004 | 6 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2012 | 975 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2024 | 87 | 0.050 |
Why?
| | Calcium | 1 | 2009 | 1213 | 0.050 |
Why?
| | Incidence | 4 | 2011 | 2644 | 0.050 |
Why?
| | Peripheral Vascular Diseases | 1 | 2003 | 102 | 0.050 |
Why?
| | Research Design | 1 | 2008 | 1044 | 0.050 |
Why?
| | Heart Ventricles | 1 | 2006 | 781 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2005 | 743 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2024 | 423 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 3794 | 0.040 |
Why?
| | Smoking | 1 | 2006 | 1501 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2024 | 672 | 0.040 |
Why?
| | Odds Ratio | 3 | 2005 | 1023 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1220 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2010 | 516 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1488 | 0.030 |
Why?
| | Adolescent | 1 | 2012 | 20393 | 0.030 |
Why?
| | Hospitals | 2 | 2009 | 637 | 0.030 |
Why?
| | United States | 3 | 2021 | 13903 | 0.030 |
Why?
| | Biomarkers | 1 | 2023 | 3973 | 0.020 |
Why?
| | Heart Failure | 1 | 2004 | 2150 | 0.020 |
Why?
| | Reminder Systems | 1 | 2012 | 174 | 0.020 |
Why?
| | Information Dissemination | 1 | 2012 | 206 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5066 | 0.020 |
Why?
| | Medication Errors | 1 | 2009 | 95 | 0.020 |
Why?
| | Mexican Americans | 1 | 2010 | 113 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 503 | 0.020 |
Why?
| | Health Surveys | 1 | 2010 | 494 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2012 | 634 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 857 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2008 | 307 | 0.020 |
Why?
| | Medical Audit | 1 | 2007 | 77 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 241 | 0.020 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2012 | 601 | 0.020 |
Why?
| | Public Policy | 1 | 2006 | 67 | 0.020 |
Why?
| | Hospitalization | 2 | 2006 | 2070 | 0.020 |
Why?
| | Smoking Prevention | 1 | 2006 | 163 | 0.020 |
Why?
| | Smoke | 1 | 2006 | 140 | 0.010 |
Why?
| | Specific Gravity | 1 | 2004 | 11 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2006 | 672 | 0.010 |
Why?
| | Exercise Test | 1 | 2006 | 613 | 0.010 |
Why?
| | Chronic Disease | 1 | 2009 | 1720 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1877 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1279 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 464 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 317 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2007 | 718 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 92 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 3144 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2006 | 407 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2003 | 161 | 0.010 |
Why?
| | Death, Sudden, Cardiac | 1 | 2003 | 179 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2002 | 271 | 0.010 |
Why?
| | Internet | 1 | 2005 | 617 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 358 | 0.010 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 539 | 0.010 |
Why?
| | Patient Discharge | 1 | 2007 | 857 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1004 | 0.010 |
Why?
| | Mental Disorders | 1 | 2008 | 1030 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2008 | 1022 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2003 | 1876 | 0.010 |
Why?
| | Body Mass Index | 1 | 2006 | 2273 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2003 | 679 | 0.010 |
Why?
|
|
Estacio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|